Abstract:Endoscopic eradication therapy (EET) is the standard of care for treatment of Barrett's esophagus (BE)-related neoplasia. It consists of a combination of endoscopic resection with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) followed by ablation [1]. Resection enables removal of all visible lesions that may reflect advanced neoplastic lesions. Ablation enables eradication of any remaining flat BE mucosa to achieve complete remission of intestinal metaplasia (CRIM). EMR was initially preferred given its efficiency and simplicity. ESD was later developed to enable en bloc resection regardless of lesion size, but it is technically more challenging and time consuming. In esophageal (squamous), gastric, and colonic neoplasia, ESD has been shown not only to achieve higher en bloc and R0 resection rates, but also to lower recurrence compared with EMR. However, in Barrett's neoplasia, despite en bloc resection of visible neoplastic BE lesions, the remaining flat nondysplastic BE mucosa has been shown to harbor genomic and epigenetic alterations similar to those found in resected dysplastic lesions, which could lead to progressive neoplastic transformation into high grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) if left untreated [2]. Recurrence after successful EET is well described and rates are higher (compared with those after CRIM) if only complete remission of dysplasia is achieved [3]. Hence, eradication of all intestinal metaplasia is recommended as the optimal endpoint for EET [1]. Predictors of recurrence after CRIM include older age, male sex, longer BE segments, and baseline HGD/EAC. "While ESD unequivocally allows a higher rate of en bloc R0 resection, the clinical relevance of achieving en bloc resection with ESD in BE neoplasia is likely somewhat mitigated by subsequent endoscopic ablative therapy." The optimal endoscopic resection technique in BE endotherapy remains unclear, particularly with regard to recurrence rates. Almost all comparative studies assessing recurrence rates of BE neoplasia after EMR and ESD are retrospective, making them susceptible to selection and confounding biases. While a multicenter randomized clinical trial (NCT05276791) is currently ongoing, results are not expected until 2026. The primary endpoint of this study is local recurrence 1 year after endoscopic resection. However, patients enrolled in this trial do not receive any endoscopic ablation after endoscopic resection, which is not the standard practice as per guidelines. In this issue of Endoscopy , Fujiyoshi et al. [4] report recurrence data for patients with Barrett's neoplasia (HGD or EAC) who underwent either EMR (87 patients) or ESD (70 patients) at a single tertiary referral center in Canada. Recurrence was defined as detection of HGD/EAC on follow-up after achieving complete remission of neoplasia (CRN), defined as the absence of HGD or EAC on preceding surveillance histology. In patients who achieved CRN, the rate of neoplastic recurrence (defined as HGD/EAC on surveillance biopsies) was significantly higher in the EMR group compared with the ESD group (13.0% vs. 1.9%). The mean follow-up period was less than 1 year (362 [SD 304] days) in the ESD group and only slightly longer (437 [SD 301] days) in the EMR group. Rates of "neoplastic recurrence" were higher at 1 and 2 years in the EMR group. The authors concluded that ESD reduces "recurrence" rates compared with piecemeal EMR. This study raises the important question on how recurrence should be defined in order to be clinically relevant in real-life clinical practice. It is critical to note that the primary endpoint of EET is achieving CRIM, which is defined as the absence of intestinal metaplasia on biopsies from the tubular esophagus and gastroesophageal junction in at least one surveillance endoscopy. The main rationale for achieving CRIM is to reduce the rate of (dysplastic) recurrence after successful EET, which has been shown to be substantially higher in patients who only achieve complete remission of dysplasia [3]. In almost all currently available literature comparing the outcomes of EMR and ESD for Barrett's neoplasia, including a recently published systematic review and meta-analysis [5], the standard definition of recurrence (after CRIM) has not been used. Similarly, the definition of recurrence used in the current study was the presence of HGD/EAC on surveillance biopsies after CRN (not after CRIM). As per current guidelines, true recurrence should only be determined once CRIM, the primary endpoint of EET, has been achieved, which typically requires both endoscopic resection and ablation. This standard definition of recurrence is likely more clinically relevant, allowing us to accurately distinguish true recurrence from residual disease after incomplete endoscopic treatment. Additionally, in the study by Fujiyoshi et al., CRIM -Abstract Truncated-

286 Surveillance Practices in Community and Academic Settings in Patients WHO Achieve Complete Eradication of Intestinal Metaplasia (ceim) after Radiofrequency Ablation (RFA): Results from the U.S. RFA Registry

Surveillance of patients with Barrett's esophagus after complete eradication of intestinal metaplasia

Rates of Recurrent Intestinal Metaplasia and Dysplasia After Successful Endoscopic Therapy of Barrett's Neoplasia by EMR vs ESD and Ablation: A Large North American Multicenter Cohort

Endoscopic 3D-OCT Reveals Buried Glands Following Radiofrequency Ablation of Barrett's Esophagus

S681 Identifying Predictors of On-Time Surveillance in Patients With Barrett's Esophagus Post-Endoscopic Eradication Therapy

Structural Markers Observed with Endoscopic 3-Dimensional Optical Coherence Tomography Correlating with Barrett's Esophagus Radiofrequency Ablation Treatment Response (with Videos)

Characterization of Buried Glands Before and after Radiofrequency Ablation by Using 3-Dimensional Optical Coherence Tomography (with Videos).

A Systematic Review and Meta-Analysis of the Treatment for Barrett’s Esophagus

Long-term outcomes after endoscopic treatment for Barrett’s neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period

Comparing recurrence rates between endoscopic mucosal resection and endoscopic submucosal dissection in Barrett's endoscopic therapy: timing and definitions matter!

Three-Dimensional Optical Coherence Tomography of Barrett'S Esophagus and Buried Glands Beneath Neosquamous Epithelium Following Radiofrequency Ablation

Efficacy and Safety of Cryoablation in Barrett's Esophagus and Comparison with Radiofrequency Ablation: A Meta-Analysis

Assessment of the Radiofrequency Ablation Dynamics of Esophageal Tissue with Optical Coherence Tomography

Analysis of therapeutic effect and influencing factors of radiofrequency ablation for colorectal cancer liver metastases

Ultrasound-guided quantitative fluorescence molecular endoscopy for monitoring response in patients with esophageal cancer following neoadjuvant chemoradiotherapy

Current Surveillance After Treatment is Not Sufficient for Patients With Rectal Cancer With Negative Baseline CEA

S1502: Features of Sub-Epithelial Glandular Structures on Three-Dimensional Endoscopic Optical Coherence Tomography (3D-EOCT) after Endoscopic Mucosal Ablation

Metal artefact reduction algorithm for correction of bone biopsy needle artefact in paediatric C-arm CT images: a qualitative and quantitative assessment.

AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia

547. DISEASE SPECIFIC MORTALITY OF EARLY-STAGE ESOPHAGEAL NEOPLASIA IN BARRETT’S ESOPHAGUS TREATED WITH ENDOSCOPIC THERAPY

S4065 Ten-Year Follow-Up on an Inoperable Barrett's Patient With Recurrent High-Grade Dysplasia and Esophageal Carcinoma in Situ